Saturday 17 October 2026
Export VMD’s income statement to Excel — free account
Viemed Healthcare, Inc.
VMD Healthcare Medical Devices
Viemed Healthcare, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $270.3 million, up 20.5% from fiscal 2024. In the quarter to June 2026, revenue grew 23.9%, EPS fell 12.5%, free cash flow fell 18.2% and total debt rose 65.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
9.48
0.27
−2.77%
Follow VMD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
19.40 | 19.05 | 23.62 | 30.00 |
P/S ratio |
1.03 | 1.07 | 1.24 | 1.45 | |
P/FCF ratio |
11.26 | 10.29 | 9.74 | 12.66 | |
P/Operating CF |
14.28 | 15.67 | 43.85 | 27.42 | |
P/B ratio |
1.94 | 2.01 | 2.43 | 2.99 | |
Price to Tangible BV |
3.47 | 3.47 | 4.13 | 5.08 | |
EV/Sales |
1.07 | 1.07 | 1.23 | 1.43 | |
EV/EBITDA |
6.09 | 5.84 | 6.60 | 7.89 | |
EV/Operating CF |
5.62 | 5.54 | 6.19 | 7.11 | |
EV/FCF |
11.69 | 10.25 | 9.72 | 12.56 | |
Quick Ratio |
0.92 | 0.96 | 1.01 | 0.90 | |
Current Ratio |
1.13 | 1.18 | 1.22 | 1.13 | |
Net Debt/EBITDA |
0.73 | (0.07) | (0.05) | (0.29) | |
Debt/Assets |
10.45% | 6.22% | 4.66% | 3.47% | |
Debt/Equity |
0.16 | 0.09 | 0.06 | 0.05 | |
Asset Turnover |
1.37 | 1.44 | 1.53 | 1.55 | |
Operating CF/Net income |
5.23 | 3.27 | 3.13 | 5.75 | |
Capex/Depreciation |
(0.79) | (0.99) | (0.71) | (0.96) | |
Interest Coverage |
11.98 | 23.62 | 15.14 | 20.13 | |
Research and Development Expense of Revenue |
1.08% | 0.78% | 0.77% | 0.65% | |
Selling, General and Administrative Expense of Revenue |
47.42% | 45.31% | 49.38% | 50.15% | |
Intangible Assets out of Total Assets |
0.30 | 0.30 | 0.30 | 0.29 | |
Share Based Compensation of Revenue |
3.03% | 3.02% | 3.25% | 2.60% | |
Graham Net Nets |
(0.06) | (0.02) | 0.00 | (0.01) | |
Graham Number |
5.26 | 5.69 | 5.77 | 5.71 | |
Earnings Yield |
5.15% | 5.25% | 4.23% | 3.33% | |
Free Cash Flow Yield |
8.88% | 9.72% | 10.27% | 7.90% | |
Revenue per Share |
1.86 | 1.96 | 1.96 | 2.04 | |
Operating CF per Share |
0.48 | 0.47 | 0.21 | 0.42 | |
Capex per Share |
(0.15) | (0.20) | (0.14) | (0.19) | |
Free Cash Flow per Share |
0.32 | 0.28 | 0.07 | 0.23 | |
Cash per Share |
0.29 | 0.35 | 0.25 | 0.28 | |
Shareholders Equity per Share |
3.51 | 3.69 | 3.79 | 3.82 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.51 | 3.69 | 3.79 | 3.82 | |
Free Cash Flow |
12.40 | 10.83 | 2.59 | 8.62 | |
Working Capital |
5.79 | 7.44 | 9.11 | 6.07 | |
Capital Expenditures |
(5.96) | (7.61) | (5.48) | (7.29) | |
Net Current Asset Value |
(16.88) | (7.14) | (1.75) | (4.29) | |
EV/EBIT |
15.91 | 14.07 | 14.92 | 17.81 | |
Capex to Sales |
0.08 | 0.10 | 0.07 | 0.09 | |
Price to Operating Income |
15.33 | 14.13 | 14.95 | 17.96 | |
| Other line items | |||||
Average Receivables |
28.19 | 25.36 | 28.98 | 29.39 | |
Average Payables |
7.34 | 6.33 | 8.26 | 9.62 | |
Average Inventory |
4.79 | 4.68 | 4.85 | 4.80 | |
Average Assets |
185.94 | 188.11 | 187.72 | 194.41 | |
Average Common Equity |
131.15 | 138.41 | 141.27 | 143.79 |
Columns are period end dates